X0206 3/A 2022-02-14 2022-02-24 0 0001822462 Foghorn Therapeutics Inc. FHTX 0001913484 Cavalie Fanny 500 TECHNOLOGY SQUARE STE #700 CAMBRIDGE MA 02139 false true false false Chief Strategy/Bus Ops Officer Stock Options (Right to buy) 14.87 2032-01-25 Common Stock 125000.00 D Stock Options (Right to buy) 16.63 2031-01-27 Common Stock 50000.00 D Stock Options (Right to buy) 8.77 2030-08-17 Common Stock 59459.00 D Stock Options (Right to buy) 3.72 2029-02-12 Common Stock 10135.00 D Stock Options (Right to buy) 0.73 2028-03-27 Common Stock 5575.00 D The option vests as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until the option is fully vested. The option vests as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until the option is fully vested. The option vests as to 25% of the underlying shares of common stock on August 17, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until the option is fully vested. The option vests as to 25% of the underlying shares of common stock on January 30, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until the option is fully vested. The option vests as to 25% of the underlying shares of common stock on March 19, 2019, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until the option is fully vested. Due to an administrative error, the vesting schedule of each of the awards set forth in Table II was incorrectly described in the original Form 3 filed on February 24, 2022. This Form 3/A includes the corrected vesting schedule for each such award. This Form 3/A is also being filed to include the Reporting Person's Power of Attorney as Exhibit 24. /s /Allan Reine, M.D., Attorney-in-Fact 2022-09-09